|1.||Boucher, Paul D: 2 articles (02/2010 - 03/2002)|
|2.||Shewach, Donna S: 2 articles (02/2010 - 03/2002)|
|3.||Secrist, John A: 2 articles (02/2010 - 03/2002)|
|4.||Ladd, Brendon: 1 article (02/2010)|
|5.||Flanagan, Sheryl A: 1 article (02/2010)|
|6.||O'Konek, Jessica J: 1 article (02/2010)|
|7.||Thepsourinthone, Tico S: 1 article (02/2010)|
|8.||Im, Mike M: 1 article (02/2010)|
|9.||Yuen, Geoffrey J: 1 article (01/2008)|
|10.||Weller, Steve: 1 article (01/2008)|
12/01/1998 - "Efficacy of the carbocyclic 2'-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection."
02/01/1994 - "In another respect, however, 2'-CDG exhibited antiviral activity unlike that of ddC or PFA: a single 1-day treatment of hepatocytes with 2'-CDG blocked initiation of viral DNA synthesis for at least 8 days, irrespective of whether DHBV infection was carried out at the time of drug treatment or several days later. "
02/01/1994 - "Moreover, as for PFA and ddC, viral RNA synthesis was detected when infection was initiated in the presence 2'-CDG. "
02/01/1994 - "Like foscarnet (phosphonoformic acid [PFA]) and 2'-,3'-dideoxycytidine (ddC), 2'-CDG blocked viral DNA replication in primary hepatocyte cultures when present during an infection but failed to inhibit the DNA repair reaction that occurs during the initiation of infection to convert virion relaxed circular DNA to covalently closed circular DNA, the template for viral mRNA transcription. "
03/01/2002 - "Multi-log cytotoxicity of carbocyclic 2'-deoxyguanosine in HSV-TK-expressing human tumor cells."
02/03/2010 - "Here we have evaluated the consequences of incorporation on DNA replication and its fidelity for three structurally related deoxyguanosine analogs: ganciclovir (GCV), currently in clinical trials in a suicide gene therapy approach for cancer, D-carbocyclic 2'-deoxyguanosine (CdG) and penciclovir (PCV). "
|3.||HIV Infections (HIV Infection)
|7.||Messenger RNA (mRNA)
|8.||RNA-Directed DNA Polymerase (Reverse Transcriptase)